Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

Inclusion Criteria: * Age between 20 and 80 years * Patients undergoing percutaneous coronary intervention and need to take dual antiplatelet therapy continuously at least 12weeks * Modified Lanza Score grade 0-1 measured by upper gastrointestinal endoscopy * mild gastrointestinal symptom * Creatinen in blood ≤ 3mg/dl * BUN ≤ 50mg/dl * Birilubin ≤ 3mg/dl * AST and ALT ≤ 80U/L Exclusion Criteria: * Pregnant or breast feeding * History of Stomach or esophagus surgery * Peptic ulcer or reflux esophagitis * Zollinger-Ellison syndrome or primary esophageal motility disorders * Malignant tumor * Bleeding tendency or coagulopathy * Contraindication of ALBIS * Long term use of aspirin or P2Y12 receptor antagonist within 1month * Patients who tool medicine such as PPI, APA,H2blocker, Muscarine receptor antagonist, anti-gastic agent, antacid, anticaogulant, Bisphosphonate agents, Cytotoxic drug, NSAID, adrenal cortex hormone agents (topical treatment is allowed) * Terminal patient